|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200058680 |
|
最近更新日期: Date of Last Refreshed on: |
2023-02-06 09:46:03 |
|
注册时间: Date of Registration: |
2022-04-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国工作场所癌症预防综合干预项目 |
|
Public title: |
Comprehensive workplace intervention for cancer prevention in China |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国工作场所癌症预防综合干预项目 |
|
Scientific title: |
Comprehensive workplace intervention for cancer prevention in China |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
孙凯歌 |
研究负责人: |
吴静 |
|
Applicant: |
Kaige Sun |
Study leader: |
Jing Wu |
|
申请注册联系人电话: Applicant telephone: |
15201277750 |
研究负责人电话:
Study leader's |
01083154663 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
ksun@georgeinstitute.org.cn |
研究负责人电子邮件: Study leader's E-mail: |
wujing@ncncd.chinacdc.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市朝阳区亮马河南路14号塔园外交办公楼1单元052A室 |
研究负责人通讯地址: |
北京市西城区南纬路27号 |
|
Applicant address: |
Room 052A, Unit 1 Tayuan Diplomatic Office Building No. 14 Liangmahe Nan Lu, Chaoyang District Beijing |
Study leader's address: |
27 Nanwei Road, Xicheng District Beijing, People's Republic of China |
|
申请注册联系人邮政编码: Applicant postcode: |
100600 |
研究负责人邮政编码: Study leader's postcode: |
100050 |
|
申请人所在单位: |
乔治全球健康研究院(澳大利亚)北京代表处 |
||
|
Applicant's institution: |
The George Institute for Global Health (Australia) Beijing Representative Office |
||
|
研究负责人所在单位: |
中国疾病预防控制中心慢性非传染性疾病预防控制中心 |
||
|
Affiliation of the Leader: |
National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
202210 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国疾控中心慢病中心伦理审查委员会 |
||
|
Name of the ethic committee: |
NATIONAL CENTER FOR CHRONIC AND NONCOMMUNICABLE DISEASE CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION ETHICAL REVIEW COMMITTEE |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-05-24 00:00:00 | ||
|
伦理委员会联系人: |
王若涛 |
||
|
Contact Name of the ethic committee: |
Ruotao Wang |
||
|
伦理委员会联系地址: |
北京市西城区南纬路27号 |
||
|
Contact Address of the ethic committee: |
27 Nanwei Road, Xicheng District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
中国疾病预防控制中心慢病中心 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
National Centre for Chronic and Non-communicable Disease Control and Prevention (NCNCD), China CDC |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市西城区南纬路27号 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
27 Nanwei Road, Xicheng District, Beijing |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
英国医学研究理事会;全球慢性病合作联盟 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
Medical Research Council (MRC); Global Alliance for Chronic Diseases (GACD) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
癌症 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Cancer |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
整群随机分组 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Cluster randomization |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
基于现有的有循证依据的工作场所防癌控癌的健康促进策略,探索适用于中国和其他中低收入国家的工作场所癌症综合预防模式。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
The primary aim of our study is to adapt existing evidence-based strategies of workplace health promotion in the prevention and control of cancer and build a scalable model in China and other LMICs. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
(1)全职员工人数>100人; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
1) Number of full-time employees > 100; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
无 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
No |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-03-01 00:00:00至 To 2025-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-03-01 00:00:00 至 To 2023-04-15 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究设计为阶梯楔形整群随机对照试验设计,随机化工作通过SAS软件进行。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Using the stepped wedge cluster randomised controlled trial design, the 15 workplaces will be randomly allocated to 3 groups and one of the groups will be randomly selected to start the intervention sequence every 6 months. Randomization will be performed by SAS software. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放 |
|
Blinding: |
Open-label |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC采集 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All the data collection will be conducted via the tailored mobile application. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |